

CURRICULUM VITAE
JEFFREY STUART DOME, MD, PhD

PERSONAL DATA

Home Address: 11206 Welland Street
North Potomac, MD 20878
301-424-3017

Office Address: Children's National Medical Center
Center for Cancer and Blood Disorders
111 Michigan Ave NW
Washington, DC 20010
Phone: 202-476-2800
Fax: 202-476-5685
jdome@cnmc.org

Citizenship: United States

EDUCATION

B.A.	1983-1987	University of Pennsylvania, Philadelphia, PA (cum laude with Honors in Biochemistry)
M.D.	1987-1991	University of Pennsylvania School of Medicine, Philadelphia, PA
Residency (Pediatrics)	1991-1994	Department of Pediatrics, Yale-New Haven Hospital, New Haven, CT
Fellowship (Hematology/Oncology)	1994-1997	Departments of Pediatrics & Oncology, Johns Hopkins Hospital, Baltimore, MD
PhD	2008-2009	Medicine, Erasmus University of Rotterdam, The Netherlands
Leadership	2013-2014	Pediatric Leadership Development Program, Association of Medical School Pediatric Department Chairs (AMSPDC)

EMPLOYMENT

1997-1998	Assistant Faculty, Departments of Pediatrics and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
1998-2004	Assistant Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN
2004-2006	Associate Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN
2006-present	Chief, Division of Oncology, Center for Cancer and Blood Disorders, Children's National Medical Center
2006-2008	Interim Chief, Division of Hematology, Center for Cancer and Blood Disorders, Children's National Medical Center
2012-2017	Chief, Division of Hematology, Center for Cancer and Blood Disorders, Children's National Health System
2016-present	Vice President, Center for Cancer and Blood Disorders, Children's National Health System

ACADEMIC APPOINTMENTS

1998-2004	Assistant Professor, Department of Pediatrics, University of Tennessee Health Science Center College of Medicine
2005-2006	Associate Professor, Department of Pediatrics, University of Tennessee Health Science Center College of Medicine
2007-2010	Associate Professor with tenure, Department of Pediatrics, George Washington University School of Medicine and Health Sciences
2010-present	Professor with tenure, Department of Pediatrics, George Washington University School of Medicine and Health Sciences
2011-present	Thomas Willson and Lenore Williams McKnew Professor of Pediatric Oncology, Children's National Medical Center

PROFESSIONAL REGISTRATIONS, LICENSES, AND CERTIFICATION

Diplomate, National Board of Medical Examiners, 1992
Diplomate, American Board of Pediatrics (inactive)

Diplomate, American Board of Pediatrics, Subboard of Pediatric Hematology-Oncology,
Maintenance of Certification renewed 2012
Medical Licensure, State of Tennessee, Expiration July 2007
Medical Licensure, State of Maryland
Medical Licensure, District of Columbia

SOCIETIES

National Wilms Tumor Study Committee, 1998-2001

Children's Oncology Group, 2001-present

- Member, Young Investigator Committee, 2002-2004
- Member, Biopathology and Translational Research Committee, 2001-2006
- Chair, Renal Tumor Biology Committee, 2002-2006
- Vice Chair, Renal Tumor Committee, 2002-2006
- Chair, Renal Tumor Committee, 2006-2016
- Study Chair, AREN0321, Therapy for high-risk renal tumors, 2006-present
- Study Vice-Chair, AREN03B2, Renal tumor biology study, 2006-2009
- Study Committee, AREN0534, Therapy for Bilateral Wilms tumor, 2005-present
- Principal Investigator, Children's National Medical Center, 2009-present
- Study Committee ADVL1121
- Study Committee, ADVL1522
- Study Committee, AREN1721
- Study Committee, AREN1921
- Nominating Committee (elected), 2014-2017
- Executive Committee (elected), 2017-present
- Scientific Council, 2018-present

International Society of Pediatric Oncology (SIOP), 2007-present

- Scientific Program Advisory Committee, 2011-present
- Chair, Organizing Committee for International Congress, Washington, DC, 2017

American Society of Clinical Oncology, 1997-present

- Grants Selections Committee, 2006-2009
- Executive Committee, Grants Selections Committee, 2008-2009

Society for Pediatric Research, 2007-present

International WAGR Syndrome Association

- Medical Advisory Board, 2012-present

American Board of Pediatrics

- Sub-board member, Pediatric Hematology/Oncology, 2013-present
- Chair, 2017-present

The Pablove Foundation

- Medical Advisory Board, 2013-present

HONORS

Westinghouse Science Talent Search, Semi-Finalist, 1983

Benjamin Franklin Scholar, University of Pennsylvania, elected 1984

Phi Lambda Upsilon Honorary Chemistry Society, elected 1987

Mortar Board Senior Honor Society, elected 1987

American Cancer Society Clinical Fellow, 1994-1995

Samuelson Fellow in Pediatric Oncology, Johns Hopkins University, 1997

American Society of Clinical Oncology, Young Investigator Award, 1997

Giulio D'Angio Award, 1999

Society for Pediatric Research, selected 2008

Best Doctors in America, selected 2009

Castle Connolly, Best Doctors, selected 2011

Thomas Willson and Lenore Williams McKnew Professor of Pediatric Oncology, 2011

Best Doctors, Washingtonian Magazine, 2015 and 2018

Best Doctors, Northern Virginia Magazine, 2015-2018

ADMINISTRATIVE DUTIES & UNIVERSITY ACTIVITIES

2000-2001 St. Jude Critical Care Committee

2000-2002 St. Jude Post-Doctoral Advisory Committee

2003-2004 St. Jude Clinical Protocol Scientific Review and Monitoring Committee

2001-2002 St. Jude Cancer Committee

2000-2006 St. Jude Tissue Resource Committee

○ Committee Chair, 2005-2006

2004-2006 St. Jude Institutional Review Board

○ Vice-Chair, 2005-2006

2006-present Chief, Division of Oncology, Children's National Medical Center

2006-2008 Interim Chief, Division of Hematology, Children's National Medical Center

2007-2008 Medical Unit Director, Hematology/Oncology Unit, Children's National Medical Center

2007-2011 Research Advisory Committee Grant Review Committee, Children's National Medical Center

2008-2012 Master Mentor Committee, Children's National Medical Center

2011-2012	Search Committee for Director, Center for Cancer and Immunology Research
2012-2017	Chief, Division of Hematology, Children's National Medical Center
2013-present	Search Committee for Chief of Division of Infectious Diseases
2013-2014	Governance Committee for allocation of faculty effort (Clinical, Administration, Scholarship, Education)
2013-present	Associate Director, Center for Cancer and Immunology Research, Children's National Medical Center
2016-present	Vice-President, Center for Cancer and Blood Disorders

EDUCATIONAL ACHIEVEMENTS

Courses Taught

2001-2006	Lecturer, Pediatric Oncology Nursing Course, St. Jude Children's Research Hospital
2003-2006	Course Director, Tumor Board, St. Jude Children's Research Hospital
2009	Lecturer, Children's National Medical Center Annual Meeting, CME course for pediatricians
2009-2012	Lecturer, Children's National Medical Center Pediatric Board Review
2007-present	Hematology/Oncology Lecture series for pediatrics residents, Co-developed curriculum, regular lecturer
2007-present	Fellow Boot Camp, Pediatric Solid Tumors

Fellows Mentored

2003-2005	Robert Sanders, MD (Pediatric Hematology/Oncology Fellow) Telomere Maintenance Mechanisms in Osteosarcoma
2003-2005	Monika Metzger, MD (Pediatric Hematology/Oncology Fellow) Phase II study of Topotecan for Recurrent Wilms Tumor (WILTOP)
2002-2004	James Geller, MD (Pediatric Hematology/Oncology Fellow) Cooperative Group Trial for Pediatric Renal Cell Carcinoma
2007-2010	Manpreet Ahluwalia, MD (Faculty advisor and member of Scholarship Oversight Committee)
2008-2011	Theresa Watson, MD (Faculty advisor and member of Scholarship Oversight Committee)
2010-2013	Srivandana Akshintala, MD (Faculty advisor)
2014-2017	Marie Nelson, MD (Pediatric Hematology/Oncology Fellow)
2019-present	Liny John, MD (Pediatric Hematology/Oncology Fellow)

Students Mentored

1997-1998	Paul Cheung (Johns Hopkins University)
1999	Todd Heaton (University of Virginia)

2000-2001	Scott Baker (George Washington University School of Medicine)
2002	Jennifer Simpson (Crichton College)
2004	Peter Gayad (University of Illinois, Urbana Champagne)
2005-2006	Robert Allen (University of Tennessee)
2006	Marie Vervaeke (Notre Dame University)
2010-2013	Nishant Garg (Thomas Jefferson High School of Science)
2010-2013	Sriram Sundararaman (Thomas Jefferson High School of Science)
2013-2014	Anna Oguehebe (National Institutes of Health)
2015	Ethan Steinberg (University of Chicago)

CONSULTANT APPOINTMENTS

Editorial Board, *Pediatric Blood and Cancer*, 2018-present

Ad hoc journal reviewer (averaging 1 review per month):

American Journal of Hematology
Cancer
Cancer Research
Clinical Cancer Research
European Journal of Cancer
International Journal of Cancer
Journal of Clinical Oncology
Journal of Neuro-Oncology
Journal of Pediatrics
Journal of Pediatric Hematology-Oncology
Leukemia
Medical and Pediatric Oncology
Nature Communications
Pediatric Blood and Cancer
Pediatric Nephrology
Pediatrics

Grant Reviewer:

2005 NIH Study Section ZRG1 F09, Fellowship: Oncological Sciences

2003-present Cancer Research UK

2006-2009 American Society of Clinical Oncology Grants Selection Committee

2010-present Alex's Lemonade Stand Foundation Grants Selection Committee

2010-present Pablove Foundation

2012-present CureSearch Foundation

2013-present Rally Cancer Foundation

2017-present Hyundai Hope on Wheels Foundation

GRANT SUPPORT

Current

U10CA180886 (Adamson, PI) 3/1/14-2/28/19, 10% effort

Children's Oncology Group Study Chair Grant

Role: Co-Investigator

This grant supports my role as Institutional PI for Children's Oncology Group studies at Children's National Health System

U10 CA180884 (Adamson/Skapek, PI) 3/1/2014 – 2/28/2019, 2% effort

COG NCTN Solid Malignancy Integrated Translational Science Award

Role: Co-Investigator

This grant supports Dr. Dome's efforts on the COG Solid Malignancy Integrated Translational Science Committee

RO1 CA219013-01 (Kalapurakal, PI) 7/1/2017- 6/30/2022, 5% effort

Retrospective NCI Phantom-Monte Carlo Dosimetry for Late Effects in Wilms Tumor

Role: Co-Investigator

This grant supports a study to correlate organ dose of radiation therapy with long term toxicity in survivors of Wilms tumor

Children's Cancer Foundation (Dome, PI) 10/1/19- 9/20/20

Fertility Friends Grant

Role: Principal Investigator

This grant supports develop of a fertility preservation program at Children's National

Pending

Alex's Lemonade Stand Foundation (Dome, PI) 2/1/20- 1/31/22

Metformin as a Chemopreventive Agent for Wilms Tumor

Role: PI (multi-PI grant with Vicki Huff, PhD)

Past

U10CA180886 (Adamson, PI) 3/1/14-2/28/17, 10% effort

Children's Oncology Group Study Chair Grant

Role: Co-Investigator

This grant supported Dr. Dome's involvement as Disease Committee Chair of the COG Renal Tumor Committee.

NIH U10 CA98543, Children's Oncology Group, Principal Investigator, Children's National Medical Center, 3/1/09-2/28/14, 15% effort (Subcontract)

NIH U10 CA98543, Children's Oncology Group, Chair, Renal Tumor Committee, 3/1/03-2/28/14, \$29,506/year, 10% effort (Subcontract)

NIH U10 CA98543, Children's Oncology Group, Chair, AREN0321 Study, 3/1/03-2/28/14, \$14,753/yr, 5% effort (Subcontract)

Board of Visitors Award, 2013-2014, \$300,000/year, Personalized Medicine for Pediatric Cancer (Co-Investigator with Dr. Yang Liu)

CureSearch Research Infrastructure Award, 1/1/14/12/31/15, \$20,000/year (Principal Investigator)

NIH U10 CA98543-07S6 (ARRA award) Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Wilms Tumor Project, 9/1/09-8/31/2012 (no cost extension) \$9768/yr, 3% effort (Subcontract)

Children's Cancer Foundation, "Telomerase as a Therapeutic Target for Pediatric Cancer," 10/1/09-9/30/2011, \$192,000, 10% effort (Principal Investigator)

Children's National Medical Center, Board of Visitors Grant, Telomerase as Therapeutic Target for Pediatric Solid Tumors, 2008, \$13,000, (Principal Investigator)

NIH, R21 CA98543-02, Telomere Maintenance Mechanisms in Osteosarcoma, 9/1/2005-8/31/2009, \$83,979/year (Principal Investigator)

Children's Oncology Group, Telomerase as a Therapeutic Target for Pediatric Cancer, 3/1/07-2/28/08, \$50,000/yr (Principal Investigator)

Glaxo Smith Kline, Phase II Study of Topotecan for Recurrent Wilms Tumor, 9/1/05-8/31/07, \$30,000/yr (Principal Investigator)

NIH, P01 CA23099, Clinical phase I-II Studies in Children and Adolescents, 7/01/02-6/30/07, \$96,967/yr (Co-Investigator)

NIH, RO1 CA087903, Telomerase as a prognostic indicator for Wilms tumor, 8/01/00-7/31/05, \$150,000/yr (Principal Investigator)

NIH, U10 CA42326, DNA ploidy as a prognostic marker for Wilms tumor, 6/8/00-5/31/03, \$26,329/yr (Co-Investigator)

NIH, U10CA 78933, Telomerase as a prognostic marker for Wilms tumor, 8/1/98-7/31/00, \$80,563/yr (Co-Investigator)

ASCO, Young Investigator Award, Telomerase as a prognostic marker for Wilms tumor, 8/1/97-7/31/98, \$30,000 (Principal Investigator)

PUBLICATIONS

Papers in Refereed Journals

1. Dome JS, Mittal B, Pochapin M, Sanger J, Sanger J. Incorporation of fluorescently labeled actin and tropomyosin into muscle cells. *Cell Differ* 23:37-52, 1988.
2. Sanger J, Dome JS, Mittal B, Somlyo A, Sanger J. Dynamics of the endoplasmic reticulum in living non-muscle and muscle cells. *Cell Motil Cytoskeleton* 13:301-319, 1989.
3. Sanger J, Mittal B, Dome JS, Sanger J. Analysis of cell division using fluorescently labeled actin and myosin in living PtK2 cells. *Cell Motil Cytoskeleton* 14:201-219, 1989.
4. Sanger J, Dome JS, Hock R, Mittal B, Sanger J. Occurrence of fibers and their association with talin in the cleavage furrows of PtK2 Cells. *Cell Motil Cytoskeleton* 27:26-40, 1994.
5. Varon D, Jiang C, Hedican C, Dome JS, Umbricht CB, Carey LA, Thompson HJ, Sukumar S. Telomerase activity in the normal and neoplastic rat mammary gland. *Cancer Res* 57:5605-5609, 1997.
6. Sanger JM, Dome JS, Sanger JW. Unusual cleavage furrows in tissue culture cells - insights into the mechanisms of cytokinesis. *Cell Motil Cytoskeleton* 39 (2):95-106, 1998.
8. Carey LA, Hedican CA, Henderson GS, Umbricht CB, Dome JS, Varon D, Sukumar S. Careful histologic confirmation and microdissection reveal telomerase activity in other telomerase-negative breast cancers. *Clinical Cancer Research* 4:435-440, 1998.
9. Dome JS and Look AT. Three molecular determinants of malignant conversion and their potential as therapeutic targets. *Current Opinion in Oncology* 11:58-67, 1999.
10. Umbricht CB, Sherman M, Dome JS, Carey LA, Adey C, Kim N, and Sukumar S. Telomerase activity in ductal carcinoma in situ and invasive cancer of the breast. *Oncogene* 18:3407-3414, 1999.
11. Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, Grundy P, Perlman EJ, Breslow NE, and Sukumar S. High telomerase reverse transcriptase (hTERT) and mRNA level correlates with disease recurrence in patients with favorable histology Wilms tumor. *Cancer Research* 59:4301-4307, 1999.

12. Carey LA, Kim NW, Goodman S, Marks J, Henderson G, Umbricht CB, Dome JS, Dooley W, Amshey SR, and Sukumar S. Telomerase activity and prognosis in primary breast cancers. *Journal of Clinical Oncology* 17:3075-3081, 1999.
13. Gow KW, Dome JS, Iglesias J, Novick WM, Hoffer FA, and Davidoff AM. Intraatrial and intracaval Wilms' tumor, *J. Pediatr Surg* 36:1869-1871, 2001
14. Dome JS and Coppes, MJ. Recent advances in Wilms tumor genetics. *Current Opinion in Pediatrics*, 14:5-11, 2002.
15. Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw N, Billups CA, and Wilimas JA. Improved survival for patients with recurrent Wilms tumor, *J. Pediatr Hematol Oncol*, 24: 192-198, 2002.
16. Rodriguez-Galindo C, Daw N, Kaste SC, Meyer WH, Rao BN, Dome JS, Pappo AS, and Pratt CB. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide, *J. Pediatr Hematol Oncol* ,24:250-255, 2002.
17. Wagner L, Hill DA, Fuller C, Pedrosa M, Bhakta M, Perry A, and Dome JS. Treatment of metastatic rhabdoid tumor of the kidney, *J. Pediatr Hematol Oncol*, 24: 385-388, 2002.
18. Muwakkit S, Antillon F, Valverde P, Jenkins JJ, Zaatari G, and Dome JS. Simultaneous Wilms tumor and rhabdomyosarcoma in two patients, *Med Pediatr Oncol*, 39: 143-145, 2002.
19. Loeb DM, Hill DA, and Dome JS. Complete response of cellular congenital mesoblastic nephroma to chemotherapy, *J. Pediatr Hematol Oncol* , 24: 478-481, 2002.
20. Dome JS, Hill DA, and McCarville MB. Rhabdoid tumor of the kidney, *eMedicine Journal*, 3, <http://www.emedicine.com/ped/topic3012.htm>, 2002.
21. Ehrlich M, Jiang G, Fiala E, Dome JS, Yu M., Long T, Youn B, Sohn O, Widschwendter M, Tomlinson G, Chintagumpala M, Champagne M, Parham D, Liang G, Malik, K, and Laird P, Hypomethylation and hypermethylation of DNA in Wilms tumors, *Oncogene*, 21: 6694-6702, 2002.
22. Ehrlich M, Hopkins NE, Jiang G, Dome JS, Yu MC, Woods CB, Tomlinson GE, Chintagumpala M, Champagne M, Diller L, Parham DM, and Sawyer J. Satellite DNA hypomethylation in karyotyped Wilms tumors, *Cancer Genet Cytogenet*, 141:97-105, 2003.
23. Hill DA, Shear TD, Liu T, Billups CA, Singh, PK, and Dome JS. Clinical and biological significance of nuclear unrest in Wilms tumor, *Cancer*, 97: 2318-2326, 2003.

24. Mihara K, Imai C, Coustan-Smith E, Dome JS, Vanin E, and Campana D. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase, *British J Hematol*, 120:846-849, 2003.
25. Okamoto Y, Mathew S, Daw NC, Neel MN, McCarville ME, Dome JS, and Hill DA. Giant cell tumor of bone with pulmonary metastases, *Med Pediatr Oncol*, 41: 454-459, 2003.
26. Dome JS and Huff V. Wilms Tumor Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2003. Available at <http://www.genetests.org>, 2003.
27. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary. *Clinical Cancer Research* 9: 5442-5453, 2003.
28. Kalapurakal J, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, and Coppes MJ. Management of Wilms tumor: Current practice and future goals. *Lancet Oncology* 5: 37-46, 2004.
29. Corey B, Yang C, Wilimas JA, Davidoff, A, and Dome JS. Significance of pleural effusion at diagnosis of Wilms tumor. *Pediatr Blood Cancer* 42:145-148, 2004.
30. Bakkenist CJ, Drissi R, Wu J, Kastan MB, and Dome JS. Disappearance of the Telomere dysfunction-induced stress response in fully senescent cells. *Cancer Res* 64: 3748-3752, 2004.
31. Geller JI and Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. *Cancer* 101:1575-1583, 2004
32. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, and Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma, *J Clin Oncol* 22: 3790-3797, 2004.
33. Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, Thomas P, Beckwith JB, D'Angio GJ, and Green DM. Age at diagnosis as a prognostic factor for rhabdoid tumor of the kidney: A report from the National Wilms Tumor Study Group. *J Clin Oncol*, 23: 7641-45, 2005.
34. Dome JS, Bockhold CA, Li SM, Baker SD, Green, DM, Perlman EJ, Hill DA, and Breslow NE. High telomerase RNA expression is an adverse prognostic factor for favorable histology Wilms tumor, *J Clin Oncol*, 23: 9138-9145, 2005.

35. Metzger M and Dome JS. Current Therapy for Wilms Tumor, *The Oncologist* 10: 815-826, 2005.
36. Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, and Santana VM. Cefixime Allows Greater Dose-Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients with Refractory Solid Tumors. *J Clin Oncol*, 24: 563-570, 2006.
37. Geller JI and Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. *Pediatr Blood Cancer*, 46: 527, 2006.
38. Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Macklis R, and Green DM. Treatment of Anaplastic Histology Wilms Tumor: Results from the Fifth National Wilms Tumor Study. *J Clin Oncol*, 20:2352-2358, 2006.
39. Yamamoto M, Suzuki N, Hatakeyama N, Hori T, Kuroiwa Y, Hareyama M, Oda T, Kudoh T, Matsuno T, Hirama T, Yokoyama S, Dome JS, Tsutsumi H. Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report. *J Pediatr Hematol Oncol*, 28, 286-289, 2006.
40. Natrajan R, Little SE, Reis-Filho JS, Hing L, Messahel B, Grundy PE, Dome JS, Schneider T, Vujanic GM, Pritchard-Jones K, Jones C. Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors. *Clin Cancer Res*. 2006, Dec 15; 12(24):7284-93.
41. Dome JS, Hill DA, and McCarville MB. Malignant rhabdoid tumor. *eMedicine Journal*, <http://www.emedicine.com/ped/topic3012.htm>, 2006.
42. Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K, Jones C. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. *Cancer Res*. 2006, Dec 1; 66(23):11148-55.
43. Natrajan R, Little S, Sodha N, Reis-Filho J, Mackay A, Fenwick K, Ashworth A, Perlman E, Dome J, Grundy P, Pritchard-Jones K, Jones C. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. *J Pathol*. 2007, Jan; 211(1):52-9.
44. Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, Lovvorn HN, Dome JS, Perantoni AO. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis. *Oncogene*. 2006 Dec 7;25(58):7555-64.

45. Radulescu VC, Gerrard M, Moertel C, Grundy PE, Mathias L, Feusner J, Diller L, Dome JS. Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. *Pediatr Blood Cancer*, Epub ahead of print, January 2007.
46. Natrajan R, Williams RD, Grigoriadis A, Mackay A, Fenwick K, Ashworth A, Dome JS, Grundy PE, Pritchard-Jones K, Jones C. Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. *Genes Chromosomes Cancer* 2007 Jun 46:607-615.
47. Natrajan R, Warren W, Messahel B, Reis-Filho JS, Brundler MA, Dome JS, Grundy P, Vujanic G, Pritchard-Jones K, Jones C. Complex patterns of chromosome 9 alterations including the p16INK4A locus in Wilms tumours. *J Clin Pathol*, Epub ahead of print, April 2007.
48. Gupta H, Conrad J, Khoury JD, McGregor LM, Krasin MJ, Dome JS, Santana VM, Davidoff AM. Significance of pleural effusion in neuroblastoma. *Pediatr Blood Cancer*, Epub ahead of print, April 2007.
49. Tabori U and Dome JS. Telomere biology of pediatric cancer. *Cancer Investigation*, April 2007 25: 197-208.
50. Metzger MM, Stewart CF, Freeman BB, Billups CA, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen EA, Alvarado C, Daw NC, and Dome JS. Topotecan is active against Wilms tumor: Results of a multi-institutional phase II study. *J. Clin Oncol*, 25:3130-3136, 2007.
51. Levashova ZB, Sharma N, Timofeeva OA, Dome JS, and Perantoni AO. ELT+-CXC chemokines and their receptors in early metanephric development. *J Am Soc Nephrol*. 18: 2359-70, 2007.
52. Giel DW, Williams MA, Jones DP, Davidoff AM, and Dome JS. Renal function outcomes in patients treated with nephron sparing surgery for bilateral Wilms tumor. *J. Urol*. 178: 1786-1789, 2007.
53. Kaste SC, Dome JS, Babyn PS, Graf NM, Grundy P, Godzinski J, Levitt GA, Jenkinson H. Wilms tumour: prognostic factors, staging, therapy and late effects. *Pediatr Radiol*. 38(1): 2-17, 2008.
54. Gratias EJ and Dome JS. Current and emerging chemotherapy treatment strategies for Wilms tumor in North America. *Paediatr Drugs*. 10 (2): 115-124, 2008.
55. Davidoff AM, Giel DW, Jones DP, Jenkins JJ, Krasin MJ, Hoffer FA, Williams MA, and Dome JS. The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor: The St. Jude Children's Research Hospital Experience: 1999-2006, *Cancer*, 112:2060-2070, 2008 (article selected for accompanying editorial).

56. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC, and Khoury JD. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. *Cancer*, 113: 1453-61, 2008.
57. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds, CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche T, Seeger RC, Gilbertson R, Khan J, Smith MA, and Houghton PJ. Molecular characterization of the pediatric preclinical testing panel. *Clin Cancer Res*, 14: 4572-83, 2008.
58. Huang CC, Gadd S, Breslow N, Cutcliffe C, Sredni ST, Helenowski IB, Dome JS, Grundy PE, Green DM, Fritsch MK, and Perlman EJ. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: A report from the Renal Tumor Committee of the Children's Oncology Group. *Clin Cancer Res* 15 (5):1770-1778, 2009.
59. Fernandez CV, Anderson J, Breslow NE, Dome JS, Grundy PE, Perlman EJ, and Green DM. Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. *Pediatr Blood Cancer* 52 (2): 254-8, 2009.
60. Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, and Aldred MA. Loss of Heterozygosity at 2 q37 in sporadic Wilms tumor: a putative role for MiR-562. *Clin Cancer Res* 15 (19): 5985-92, 2009.
61. Ehrlich PF, Ferrar F, Ritchey M, Anderson J, Green D, Grundy P, Dome J, Kalapurakal JA, Perlman E, and Shamberger RC. Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor: A report from the National Wilms Tumor Study Group. *Ann Surgery*, 2009, epub ahead of print.
62. Moinul Hossain AK, Shulkin BL, Gelfand MJ, Bashir H, Daw NC, Sharp SE, Nadel HR, and Dome JS. FDG positron emission tomography/computed tomography studies of Wilms' tumor. *Eur J Nucl Med Mol Imaging*, 2010, epub ahead of print
63. Sredni ST, Gadd S, Huang CC, Breslow N, Grundy P, Green DM, Dome JS, Shamberger RC, Beckwith JB, Perlman EJ. Subsets of very low risk Wilms tumor show distinctive gene expression histologic, and clinical features. *Clin Cancer Res* 15 (22): 6800-9, 2009.
64. Spreafico F, Pritchard Jones K, Malogolowkin MH, Bergeron C, Hale J, deKraker J, Dallorso S, Asha T, de Camargo B, Dome JS, Graf N. Treatment of relapsed Wilms tumors: lessons learned. *Exp Rev Anticancer Ther* 9(12): 1807-15, 2009.
65. Kalapurakal JA, Green DM, Haase G, Anderson JR, Dome JS, Grundy PE. Outcomes of children with favorable histology Wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5. *Int J Radiat Oncol Biol Phys* 77(2): 554-8, 2010.

66. Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, Huff V. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a children's oncology group study. *J Clin Oncol* 29 (6): 698-703, 2011.
67. Fernandez CV, Li N, Mullen EA, Grundy PE, Perlman EJ, Shamberger RC, Ehrlich PF, Dome JS. Barriers to the Enrollment of Children in the Children's Oncology Group Study of Very Low Risk Wilms Tumor: A Report from the Children's Oncology Group. *J Pediatr Hematol Oncol* 33(7) 521-523, 2011.
68. Drissi R, Wu J, Hu Y, Bockhold CA, Dome JS. Telomere shortening alters the kinetics of the DNA damage response after ionizing radiation in human cells. *Cancer Prev Res*, 4(12): 1973-1981, 2011.
69. Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in wilms tumor. *Genes Chromosomes Cancer*, 50(12):982-95, 2011
70. Segers H, van den Heuvel-Eibrink MM, Pritchard-Jones K, Coppes MJ, Aitchison M, Bergeron C, de Camargo B, Dome JS, Grundy P, Gatta G, Graf N, Grundy P, Kalapurakal JA, de Kraker J, Perlman EJ, Reinhard H, Spreafico F, Vujanic G, Warwick AB; SIOP-RTSG and the COG-Renal Tumour Committee. Management of adults with Wilms' tumor: recommendations based on international consensus. *Expert Rev Anticancer Ther* 11(7), 1105-13, 2011.
71. Dome JS, Huff V: Wilms Tumor Overview in: GeneReviews at GeneTests: Medical Genetics Information Resource. Copyright, University of Washington, Seattle, 1997-2010. Available at <http://www.genetests.org>, 2011.
72. Khozeimeh N, Sinha P, Dome JS, Guzzetta PC. Strategy for management of retroperitoneal tumors with intracaval thrombus. *J. Pediatr Surg*, 46(11), 2065-2070, 2011.
73. Khanna G, Rosen N, Anderson JR, Ehrlich PF, Dome JS, Gow KW, Perlman E, Barnhart D, Karolczuk K, Grundy P. Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group. *Pediatr Blood Cancer*, 58(4):551-5, 2012.
74. Grundy PE, Green DM, Dirks AC, Berendt AE, Breslow NE, Anderson JR, Dome JS. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: A report from the Children's Oncology Group. *Pediatr Blood Cancer*, 59(4), 631-5, 2012.

75. Turnbull C, Perdeaux ER, Pernet D, Naranjo A, Renwick A, Seal S, Munoz-Xicola RM, Hanks S, Slade I, Zachariou A, Warren-Perry M, Ruark E, Gerrard M, Hale J, Hewitt M, Kohler J, Lane S, Levitt G, Madi M, Morland B, Neefjes V, Nicholsson J, Picton S, Pizer B, Ronghe M, Stevens M, Traunecker H, Stiller CA, Pritchard-Jones K, Dome J, Grundy P, Rahman N. A genome-wide association study identifies susceptibility loci for Wilms tumor. *Nat. Genet.*, 29;44(6), 681-4, 2012.
76. Kieran K, Anderson JR, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM. Lymph node involvement in Wilms tumor: Results for National Wilms Tumor Studies 4 and 5. *J. Pediatr. Surg.*, 47(4), 700-706, 2012.
77. Gooskens SL, Furtwängler R, Vujanic GM, Dome JS, Graf N, van den Heuvel-Eibrink MM. Clear cell sarcoma of the kidney: a review. *Eur J Cancer*, 48(14), 2219-26, 2012.
78. Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow N, Jennings L, Green DM, Beckwith JB, Perlman EJ. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. *Neoplasia*, 14(8), 742-56, 2012.
79. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, Buddavarapu KC, Broaddus R, Hornsby P, Tomlinson G, Dome J, Vadlamudi RK, Pertsemlidis A, Chen Y, Rao MK, Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization, *PLoS One*, 2012;7(12):e52397, 2012.
80. Kalapurakal JA, Perlman EJ, Seibel NL, Ritchey M, Dome JS, Grundy PE. Outcomes of Patients With Revised Stage I Clear Cell Sarcoma of Kidney Treated in National Wilms Tumor Studies 1-5, *Int J Radiat Oncol Biol Phys.* 85(2):428-31, 2013.
81. Ha TC, Spreafico F, Graf N, Dallorso S, Dome JS, Malogolowkin M, Furtwängler R, Hale JP, Moroz V, Machin D, Pritchard-Jones K. An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. *Eur J Cancer*, 49(1):194-210, 2013.
82. Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, Anderson JR, Naranjo A, Perlman EJ; on behalf of the COG Renal Tumors Committee, Children's Oncology Group's 2013 blueprint for research: Renal tumors., *Pediatr Blood Cancer*, 60(6):994-1000, 2013.
83. Khanna G, Naranjo A, Hoffer F, Mullen E, Geller J, Gratias EJ, Ehrlich PF, Perlman EJ, Rosen N, Grundy P, Dome JS, Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Children's Oncology Group, *Radiology*, 266(2):610-7, 2013.
84. Sadak KT, Ritchey ML, Dome JS, Paediatric genitourinary cancers and late effects of treatment, *Nat Rev Urol.* 10(1):15-25, 2012.

85. Gow KW, Barnhart DC, Hamilton TE, Kandel JJ, Chen MK, Ferrer FA, Price MR, Mullen EA, Geller JI, Gratias EJ, Rosen N, Khanna G, Naranjo A, Ritchey ML, Grundy PE, Dome JS, Ehrlich PF. Primary nephrectomy and intraoperative tumor spill: Report from the Children's Oncology Group (COG) renal tumors committee, J Pediatr Surg, 48(1):34-8, 2013.
86. Ehrlich PF, Anderson JR, Ritchey ML, Dome JS, Green DM, Grundy PE, Perlman EJ, Kalapurakal JA, Breslow NE, Shamberger RC. Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor, J Clin Oncol, 20;31(9):1196-201, 2013.
87. Malogolowkin M, Spreafico F, Dome JS, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM, Bergeron C, de Kraker J, Graf N. Incidence and outcomes of patients with late recurrence of Wilms' tumor. Pediatr Blood Cancer, 60(10):1612-5, 2013.
88. Ferrer FA, Rosen N, Herbst K, Fernandez CV, Khanna G, Dome JS, Mullen E, Gow KW, Barnhart DC, Shamberger RC, Ritchey M, Ehrlich P. Image-based Feasibility of Renal Sparing Surgery for Very Low Risk Unilateral Wilms Tumors. J Urol, 190(5):1846-51, 2013.
89. Dome JS, Huff V. Wilms Tumor Overview. 2003 Dec 19 [Updated 2013 Sep 19]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013.
90. Kieran K, Williams MA, Dome JS, McGregor LM, Krasin MJ, Davidoff AM. Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor. J Pediatr Surg, 48(7):1481-5, 2013.
91. Kieran K, Anderson JR, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM. Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Children's Oncology Group. J Pediatr Surg, 48(7):1598-603, 2013.
92. Gratias EJ, Jennings LJ, Anderson JR, Dome JS, Grundy P, Perlman EJ. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the children's oncology group. Cancer, 119(21):3887-94, 2013.
93. Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith JB, Perlman EJ, Shamberger RC, Peterson S, Grundy PE, Dome JS, Thomas PR, Kalapurakal JA. Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer, 61(1):134-9, 2014.

94. Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, de Caestecker M, Perantoni AO, Tanigawa S, Anderson JR, Dome JS, Das A, Carroll TJ, Lovvorn HN 3rd. Aberrant activation, nuclear localization, and phosphorylation of yes-associated protein-1 in the embryonic kidney and Wilms tumor. *Pediatr Blood Cancer*, 61(2):198-205, 2014.
95. Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, A Schultz K, Cathro HP, Legallo RD, Lafortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. *Mod Pathol*. 27(9):1267-80, 2014.
96. Kieran K, Williams MA, McGregor LM, Dome JS, Krasin MJ, Davidoff AM. Repeat nephron-sparing surgery for children with bilateral Wilms tumor. *J Pediatr Surg*. 49(1):149-53, 2014.
97. Graf N, Perlman EJ, Dome JS. Risk Stratification for Wilms Tumor: Current Approach and Future Directions, ASCO Education Book, 2014:215-23.
98. Ferrer FA, Herbst KW, Fernandez CV, Khanna G, Dome JS, Naranjo A, Mullen EA, Geller JI, Gratias EJ, Shamberger R, Ritchey M, Ehrlich PF. 1.Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. *J Pediatr Urol*. 10(5):969-73, 2014.
99. Hu Y, Bobb D, Lu Y, He J, Dome JS. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. *Cancer Genetics*, 207(9): 403-411, 2014.
100. Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, Pritchard-Jones K. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. *PLoS One*. 9(10):e109924, 2014.
101. Servaes S, Khanna G, Naranjo A, Geller JI, Ehrlich PF, Gow KW, Perlman EJ, Dome JS, Gratias E, Mullen EA. Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. *Pediatr Radiol*. 45(2):166-72, 2015.
102. Dean JB and Dome JS. Breast cancer in Wilms tumor survivors: New insights into primary and secondary prevention. *Cancer* 120(23): 3598-3601, 2014
103. Ortiz MV, Rossi CT, Hill DA, Guzzetta PC, Qureshi F, Dome JS. Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor. *Pediatr Blood Cancer*. 62(6):1075-7, 2015.

104. Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Bowlby R, Brooks D, Ma Y, Mungall AJ, Moore RA, Schein J, Marra MA, Huff V, Dome JS, Chi YY, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Jafari N, Ross N, Gastier-Foster JM, Perlman EJ. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. *Cancer Cell*. 9;27(2):286-97, 2015.
105. Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, Naranjo A, Dome JS, Perlman EJ. Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. *Cancer*. 15;121(14):2457-64, 2015.
106. Hu Y, Bobb D, He J, Hill DA, Dome JS. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. *Cancer Biol Ther*. 16(6):949-57, 2015.
107. Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den Heuvel-Eibrink M, Pritchard-Jones K. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. *J Clin Oncol*. 33(27):2999-3007, 2015.
108. Davidoff AM, Interiano RB, Wynn L, Delos Santos N, Dome JS, Green DM, Brennan RC, McCarville MB, Krasin MJ, Kieran K, Williams MA. Overall Survival and Renal Function of Patients With Synchronous Bilateral Wilms Tumor Undergoing Surgery at a Single Institution. *Ann Surg*. 262(4):570-6, 2015.
109. Perlman E, Gadd S, Arold S, Radhakrishnan A, Gerhard D, Jennings LJ, Huff V, Auvil JG, Davidsen T, Dome J, Meerzamen D, Hsu CH, Nguyen C, Anderson J, Ma Y, Mungall A, Moore R, Marra M, Mullighan C, Ma J, Wheeler D, Hampton O, Gastier-Foster J, Ross N, and Smith M. MLLT1 (ENL) YEATS Domain Mutations in Clinically Distinctive Favorable Histology Wilms Tumors, *Nat Comm*, Dec 4;6:10013. doi: 10.1038/ncomms10013, 2015.
110. Cajaiba MM, Khanna G, Smith EA, Gellert L, Chi YY, Mullen EA, Hill DA, Geller JI, Dome JS, Perlman EJ. Pediatric Cystic Nephromas: Distinctive Features and Frequent DICER1 Mutations. *Hum Pathol*. 48:81-7, 2016.
111. Ehrlich PF, Hamilton TE, Gow K, Barnhart D, Ferrer F, Kandel J, Glick R, Dasgupta R, Naranjo A, He Y, Perlman EJ, Kalapurakal JA, Khanna G, Dome JS, Geller J, Mullen E. Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. May 27 (epub ahead of print), 2016.
112. Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ. Association of Chromosome 1q Gain With Inferior

Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. *J Clin Oncol* 34(26): 3189-3194, 2016.

113. Ooms AH, Gadd S, Gerhard DS, Smith MA, Guidry Auvin JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Huff V, Dome JS, Chi YY, Tian J, Geller JI, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Walz AL, van den Heuvel-Eibrink MM, de Krijger RR, Ross N, Gastier-Foster JM, Perlman EJ. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. *Clin Cancer Res*, epub ahead of print, 2016.
114. Dome JS, Huff V. Wilms Tumor Predisposition. 2003 Dec 19 [Updated 2016 Oct 20]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1294/>
115. Interiano RB, McCarville MB, Santos ND, Mao S, Wu J, Dome JS, Kieran K, Williams MA, Brennan RC, Krasin MJ, Green DM, Davidoff AM. Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor. *J Pediatr Surg*. 2017 Jan;52(1):98-103.
116. Venkatramani R, Chi YY, Coppes MJ, Malogolowkin M, Kalapurakal JA, Tian J, Dome JS. Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. *Pediatr Blood Cancer*. 2017 Jan 18. [Epub ahead of print]
117. Gooskens SL, Houwing ME, Vujanic GM, Dome JS, Diertens T, Coulomb-l'Herminé A, Godzinski J, Pritchard-Jones K, Graf N, van den Heuvel-Eibrink MM. Congenital mesoblastic nephroma 50 years after its recognition: A narrative review. *Pediatr Blood Cancer*. 2017 Jan 26. [Epub ahead of print]
118. Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, Anderson JR, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. *Ann Surg*. 2017 265(4):835-840.
119. Sandberg JK, Mullen EA, Cajas MM, Smith EA, Servaes S, Perlman EJ, Geller JI, Ehrlich PF, Cost NG, Dome JS, Fernandez CV, Khanna G. Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group. *Pediatr Radiol*. 2017 Nov;47(12):1615-1621.
120. Ehrlich P, Chi YY, Chintagumpala MM, Hoffer FA, Perlman EJ, Kalapurakal JA, Warwick A, Shamberger RC, Khanna G, Hamilton TE, Gow KW, Paulino AC, Gratias EJ, Mullen EA, Geller JI, Grundy PE, Fernandez CV, Ritchey ML, Dome JS. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor

(AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017 Sep;266(3):470-478.

121. Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017 Oct;49(10):1487-1494.
122. Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS. Outcome and Prognostic Factors in Stage III Favorable Histology Wilms Tumor: A Report from the Children's Oncology Group Study AREN0532. J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6.
123. Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 Jun 1;36(16):1564-1570. doi:10.1200/JCO.2017.77.1931.
124. Cajas MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost NG, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ. The classification of pediatric and young adult renal cell carcinomas registered on the Children's Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018 Jun 15.
125. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2018 Sep 12. pii: S1558-7673(18)30384-7. doi: 10.1016/j.clgc.2018.09.005. [Epub ahead of print]
126. Iaboni DSM, Chi YY, Kim Y, Dome JS, Fernandez CV. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Pediatr Blood Cancer. 2018 Aug 30:e27430. doi: 10.1002/pbc.27430. [Epub ahead of print]
127. Mullen EA, Chi YY, Hibbitts E, Anderson JR, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV, Dome JS. Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms

Tumor: A Report From the Children's Oncology Group. J Clin Oncol. 2018 Oct 18;JCO1800076. doi: 10.1200/JCO.18.00076.

128. Armstrong AE, Gadd S, Huff V, Gerhard DS, Dome JS, Perlman EJ. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study. PLoS One. 2018 Dec 13;13(12):e0208936. doi: 10.1371/journal.pone.0208936. eCollection 2018.
129. Daw NC, Chi Y, Kim Y, Mullen EA, Kalapurakal JA, Tian J, Khanna G, Geller JI, Perlman EJ, Ehrlich PF, Warwick AB, Grundy PE, Fernandez CV and Dome JS. Treatment of stage I anaplastic Wilms tumor: a report from the Children's Oncology Group AREN0321 Study, Eur J Cancer, 2019 Sep;118:58-66. doi: 10.1016/j.ejca.2019.05.033.
130. Dix D, Fernandez CV, Chi Y, Mullen EA, Geller, JI, Gratias EJ, Khanna G, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, Anderson J, Gastier-Foster J, Shamberger R, Kim Y, Grundy PE, and Dome JS. Augmentation of therapy for favorable histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children's Oncology Group Studies AREN0532 and AREN0533. J Clin Oncol, 2019 Aug 26;JCO1801972. doi: 10.1200/JCO.18.01972. [Epub ahead of print]
131. Hont AB Cruz CR, Ulrey R,3, O'Brien B, Stanojevic M, Datar A, Albihani S, Saunders D, Hanajiri R, Panchapakesan K, Darko S, Banerjee P, Fortiz MF, Hoq F, Lang H, Yunfei Wang Y, Williams K, 3, Patrick J. Hanley PJ, Dome JS, Bollard CM, and Meany HJ. Immunotherapy of Relapsed and Refractory Solid Tumors with Ex-vivo Expanded Multi-antigen Associated Specific Cytotoxic T Lymphocytes – a Phase I Study. J Clin Oncol, 2019 Jul 29;JCO1900177. doi: 10.1200/JCO.19.00177. [Epub ahead of print]
132. Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, Heaton T, Cifani P, Dome JS, Gadd S, Perlman E, Mullen E, Steen H, Kentsis A. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. JCI Insight. 2019 Aug 8;4(15). pii: 127098. doi: 10.1172/jci.insight.127098. eCollection 2019 Aug 8.
133. Daw NC, Chi YY, Kalapurakal JA, Kim Y, Hoffer FA, Geller JI, Perlman EJ, Ehrlich PF, Mullen EA, Warwick AB, Grundy PE, Paulino AC, Gratias E, Ward D, Anderson JR, Fernandez CV, and Dome JS. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms tumor and Therapy Outcomes of Stage II-IV Disease: Results of the Children's Oncology Group AREN0321 Study. J Clin Oncol, under review.

Book Chapters

1. Dome JS, Schwartz C. Osteosarcoma. In: Walterhouse D, ed. Diagnostic and therapeutic advances in pediatric oncology. Boston: Kluwer Academic Publishers, pp 215-251, 1997.

2. Pappo A, Rodriguez-Galindo C, Dome JS, and Santana VM. Pediatric Solid Tumors. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (Ed.), Clinical Oncology. Churchill Livingstone, 2346-2401, 1999.
4. Dome JS. Wilms Tumor. In Steen RG, Mirro J (ed), The St. Jude Children's Research Hospital Handbook of Childhood Cancer: A Guide for Parents and Patients. Boston: Perseus Books, 2000.
5. Dome JS. The History and Physical Examination. In Steen RG, Mirro J (ed), The St. Jude Children's Research Hospital Handbook of Childhood Cancer: A Guide for Parents and Patients. Boston: Perseus Books, 2000.
6. Dome JS, Rodriguez-Galindo C, Spunt SL, and Santana VM. Pediatric Tumors. In Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (Ed.) Clinical Oncology. Kluwer Academic Publishers, 2004.
7. Dome JS, Perlman EJ, Ritchey ML, Coppes MJ, Kalapurakal J, and Grundy PE. Renal Tumors. In Pizzo P and Poplack D (Ed.) Principles and Practice of Pediatric Oncology, 5th edition. Lippincott, Williams and Wilkins, 2006.
8. Grundy PE, Dome JS, Kalapurakal JA, Perlman EJ, and Ritchey ML. Renal Tumors of Childhood. In Holland and Frei (Ed.) Cancer Medicine, 6th edition, 2006.
9. Kaste SC and Dome JS. PET/PET-CT imaging of Wilms tumor. In Charron M (Ed.) Pediatric PET Imaging. Springer-Verlag, 2006.
10. Dome JS, Rodriguez-Galindo C, Spunt SL, and Santana VM. Pediatric Solid Tumors. In Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (Ed.) Clinical Oncology. Elsevier Academic Publishers, 2008.
11. Grundy PE, Dome JS, Kalapurakal JA, Perlman EJ, Richey ML. Renal Tumors. In Carroll WL and Finlay JL (Ed.). Cancer in Children and Adolescents. Jones and Bartlett Publishers, 2009.
12. Dome JS, Roberts CM, and Argani P. In Orkin SH, Ginsburg D, Nathan DG, Look AT, Fisher DE, and Lux SE (Ed.) Oncology of Infancy and Childhood, Elsevier Academic Publishers, 2009.
13. Dome JS. Wilms tumor. In Wiener LS, Pao M, Kazak AE, Kupst MJ, Patenaude AF, and Holland JC (Ed.) Quick Reference for Pediatric Oncology Clinicians: The Psychiatric and Psychological Dimensions of Pediatric Cancer Symptom Management, 2009.

14. Fernandez C, Geller JI, Ehrlich PF, Hill DA, Kalapurakal JA, Grundy PE, and Dome JS. Renal Tumors. In Pizzo P and Poplack D (Ed.) Principles and Practice of Pediatric Oncology, 6th edition. Lippincott, Williams and Wilkins, 2010.
15. Gratias E and Dome JS. Renal Tumors. In Lanzkowsky P (Ed.) Manual of Pediatric Hematology and Oncology, 5th edition. Academic Press, 2011.
16. Geller JI and Dome JS. Molecularly Targeted Therapy for Wilms' Tumor. In Houghton PJ and Arceci (Ed.) Molecularly Targeted Therapy for Childhood Cancer. Springer, 2011.
17. Kalapurakal JA and Dome JS. Wilms' Tumor. In Gunderson L and Tepper J (Ed.) Clinical Radiation Oncology, 3rd edition. Elsevier Press, 2012.
18. Bambach, B, Pohl HG and Dome JS. Uncommon Pediatric Genitourinary Tumors. In Raghavan D, Blanke C, Johnson DH, Moots PL, Reaman GR, Rose, PG and Sekeres MA (Ed.) Textbook of Uncommon Cancer, 4th Edition. Wiley-Blackwell, 2012.
19. Vallance K and Dome JS. Renal Tumors of Childhood. In Finkel KW and Howard SC (Ed.) Renal Disease in Cancer Patients, Elsevier, 2013.
20. Dome JS, Rodriguez-Galindo C, Spunt SL, and Santana VM. Pediatric Solid Tumors. In Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB and Tepper JE (Ed.). Abeloff's Clinical Oncology, 5th Edition. Elsevier Press, 2014.
21. Dome JS, Gooskens SL and van den Heuvel-Eibrink, MM. Non-Wilms Pediatric Renal Tumors. In Pritchard-Jones K and Dome JS (Ed.). Renal Tumors of Childhood: Biology and Therapy, Springer, 2014.
22. Dome JS, Mullen EA and Argani P. Pediatric Renal Tumors. In Orkin SH, Fisher DE, Ginsburg D, Look AT, Lux SE and Nathan DG (Ed.). Hematology and Oncology of Infancy and Childhood, 8th Edition. Elsevier, 2015.
23. Dome JS. Wilms tumor. In Wiener LS, Pao M, Kazak AE, Kupst MJ, Patenaude AF, and Arceci RJ (Ed.) Pediatric Psycho-Oncology, 2nd Edition, Oxford University Press, 2015.
24. Kalapurakal JA and Dome JS. Wilms' Tumor. In Gunderson L and Tepper J (Ed.) Clinical Radiation Oncology, 4th edition. Elsevier Press, 2016.
25. Fernandez C, Geller JI, Ehrlich PF, Hill DA, Kalapurakal JA, and Dome JS. Renal Tumors. In Pizzo P and Poplack D (Ed.) Principles and Practice of Pediatric Oncology, 7th edition. Wolters Kluwer, 2016.
26. Dome JS and Warwick A. Renal Tumors. In Lanzkowsky P (Ed.) Manual of Pediatric Hematology and Oncology, 6th edition. Academic Press, 2016.

27. Kim A, Dome JS and Meany H. Chemotherapy and Multidisciplinary Approaches to Pediatric Sarcomas. In Henshaw R (ed.). Sarcoma: A Multidisciplinary Approach to Treatment, Springer, 2017.
28. Pohl HG and Dome JS. Uncommon Pediatric Genitourinary Tumors. In Raghavan D, Ahluwalia MS, Blanke CD, Brown J, Kim ES, Reaman GR, and Sekeres MA (Ed.) Textbook of Uncommon Cancer, 5th Edition. Wiley-Blackwell, 2017.
29. Nelson MV and Dome JS. Renal Tumors. In Kline MW, Blaney SM, Giardino AP, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS, Rudolph AM, Rudolph CM (ed.) Rudolph's Pediatrics, 23rd Edition, McGraw Hill, 2018.
30. Nelson MV, Verschuur A and Dome JS. Wilms Tumor. In Molouf G and Tannir N (ed). Rare Renal Tumors, Springer-Nature, 2018.
31. Dome JS, Rodriguez-Galindo C, Spunt SL, and Santana VM. Pediatric Solid Tumors. In Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB and Tepper JE (Ed.). Abeloff's Clinical Oncology, 6th Edition. Elsevier Press, 2020.

Books Written or Edited

1. Coppes MJ and Dome JS (Ed.). Pediatric Clinics of North America, February, 2008.
2. Dome JS. Identification and management of high-risk Wilms tumors, PhD Thesis, Erasmus University, Rotterdam, 2009.
3. Coppes MJ, Ware RE, and Dome JS (Ed.). Hematology/Oncology Clinics of North America, February, 2010.
4. Pritchard-Jones K and Dome JS (Ed.). Renal Tumors of Childhood: Biology and Therapy, Springer, 2014.

Letters/Editorials

1. Geller JI, Khoury JD, and Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma: Author Reply. Cancer 103: 1317-1318, 2005.
2. Kaste SC, Dome JS, Babyn PS. In reply. Pediatr Radiol. 38: 484-485, 2008.
3. Geller JI and Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer 52 (3): 430, 2009.

4. Dean JB, Dome JS. Reply to Wilms tumor and breast cancer. *Cancer*. 15;121(12):2100-1, 2015.
5. Dome JS and D'Angio. In Memoriam: Norman E. Breslow, PhD (1941-2015): In Memoriam. *Pediatr Blood Cancer* . 63(8):1491, 2016.
6. Dean JB and Dome JS. Commentary, Breast Cancer in Female Survivors of Wilms Tumor. In Cabana M, Goldstein AM, Scemama de Gialluly P, Schoeder AR (Ed.) *Yearbook of Pediatrics*, Elsevier Mosby, 2016.
7. Fernandez CV, Perlman EJ, Gastier-Foster J, Geller JI, Mullen EA, Ehrlich PF, Dome JS. Reply to B. Zhang et al. *J Clin Oncol*. 2018 May 10;36(14):1454-1455.
8. Dix DB, Seibel NL, Chi YY, Khanna G, Mullen EA, Geller JI, Kalapurakal JA, Ehrlich PF, Malogolowkin MH, Fernandez CV, Dome JS. Reply to D.M. Green. *J Clin Oncol*. 2018 Sep 13;JCO1800659. doi: 10.1200/JCO.18.00659.
9. Mullen EA, Khanna G, Geller JI, Fernandez CV, Dome JS. Reply to L. Xie et al. *J Clin Oncol*, 2019 Mar 15;JCO1900012. doi: 10.1200/JCO.19.00012. [Epub ahead of print]

Abstracts (selected)

1. Sanger JM, Mittal B, Pochapin M, Dome JS, & Sanger JW. Myogenesis in Living Cells Microinjected with Fluorescently Labeled Contractile Proteins. *J.Cell Biol.*, 101,173a, 1985.
2. Sanger JM, Mittal B, Weisberg A, Dome JS, & Sanger JW. In situ Localization of Actomyosin Bundles in Rat Kidney and Intestine. *J. Cell Biol.*, 103, 203a, 1986.
3. Dome JS, Mittal B, Ng M, Southwick F, Sanger JM, & Sanger JW. Myofibrillogenesis. *J. Cell Biol.*, 105, 27a, 1987.
4. Sanger JM, Dome JS, Mittal B, & Sanger JW. Dynamics of Actin, Myosin, and membranes in Living Cells During Cell Division. *Biol. Bull.*, 173, 421, 1987.
5. Sanger JM, Dome JS, Somlyo A, & Sanger JW. Dynamics of the Endoplasmic Reticulum in Living Cells. *J. Cell Biol.*, 105, 87a, 1987.
6. Sanger JM, Dome JS, Mittal B, Sanger JW. Assembly and changes in the fibrous substructure of the cleavage furrow in living cells. *Biol Bull* 175:302-303, 1988.
7. Sanger JM, Mittal B, Dome JS, Sanger JW. Changes in distribution of elements of the cytoskeleton in dividing cells. *J Cell Biol* 107:432a, 1988.

8. Sanger JW, Sanger JM, Mittal B, Dome JS, Ng M, Lee SK. Use of fluorescent probes to study myofibrillogenesis. J. Cell. Biochem. Suppl. 12C: 306, 1988.
9. Sanger JM, Mittal B, Dome JS, Sanger JW. Dynamics of the cytoskeleton and membranous organelles in cell division. Eur. J. Cell Biol. 48 (Suppl 26), 57, 1989
10. Sanger JM, Dome JS, Sanger JW. Cytokinesis in multipolar cells. Mol. Biol. Cell 5:158a, 1995.
11. Dome JS, Perlman E, Sukumar S. Telomerase activity as a potential prognostic marker in Wilms tumor. Proceedings ASPHO 5:34, 1996.
12. Varon D, Adey C, Jiang C, Thompson HJ, Guzman RC, Dome J, Carey L, Umbricht C, Sukumar S. Telomerase as an early marker in N-Methyl-N'nitrosourea-induced mammary carcinogenesis. Proceedings AACR 38:209, 1997.
13. Umbricht C, Carey L, Henderson G, Dome J, Varon D, Adey C, Sukumar S. Telomerase activity in preinvasive breast cancer. Proceedings AACR 38:506, 1997.
14. Carey LA, Adey C, Henderson G, Umbricht CB, Dome JS, Varon D, Sukumar S. Microdissection reveals telomerase activity in otherwise telomerase negative breast cancers. Proceedings AACR 38:636, 1997.
15. Dome JS, Perlman EJ, Adey C, Carey LA, Umbricht CB, Varon D, Sukumar S. Telomerase activity as a predictor of relapse in Wilms tumor. Proceedings AACR 38:505, 1997.
16. Dome JS, Hedican CA, Umbricht CB, Chung P, Perlman E., The National Wilms Tumor Study Group, Sukumar S. An analysis of the prognostic value of telomerase enzyme activity levels, hTR levels, and hTERT mRNA levels in Wilms tumor. Proceedings AACR 39:451, 1998.
17. Carey LA, Kim NW, Goodman S, Marks J, Henderson G, Umbricht CB, Dome JS, Amshey SR, Sukumar S. Telomerase activity as a prognostic marker in breast cancer. Proceedings AACR 39:543, 1998.
1. Umbricht CB, Sherman M, Dome J, Adey C, Kim N, Sukumar S. Telomerase activity in preinvasive breast cancer. Proceedings AACR 39:543, 1998.
2. Dome JS, Hedican CA, Umbricht CB, Chung P, Perlman EJ, The National Wilms Tumor Study Group, & Sukumar S. An analysis of the prognostic value of telomerase enzyme activity levels, hTR levels, and hTERT mRNA levels in Wilms tumor. Proceedings AACR, 39:541, 1998.

3. Drissi R, Dome JS, White EL, & Cleveland JL. The regulation of telomerase activity by c-myc is cell context specific. Telomeres and Telomerase. Cold Spring Harbor Meeting, March, 1999.
4. Dome JS, Chung S, Bergemann T, Umbricht CM, Saji M, Carey LA, Grundy P, Perlman EJ, Breslow NE, & Sukumar S. Telomerase reverse transcriptase (hTERT) mRNA levels correlate with outcome in patients with favorable histology Wilms tumor. 3rd International Conference on the Clinical and Molecular Genetics of Childhood Renal Tumors, Philadelphia, PA, April, 1999.
5. Hopkins NE, Sawyer JR, Dome J, Chintagumpala M, Tomlinson GE, Champagne M, and Ehrlich M. Chromosome abnormalities and DNA methylation changes in Wilms tumors. Proceedings AACR, 42: 477, 2001.
6. Drissi R, Roussel MF, Dome JS, and Cleveland JL. hTERT inhibits telomerase activity and cell growth in both primary and immortalized murine cells. Telomeres and Telomerase, Cold Spring Harbor Meeting, March, 2001.
7. Loeb DM, Hill DA, and Dome JS. Complete response of cellular congenital mesoblastic nephroma to chemotherapy, American Society of Pediatric Hematology/Oncology Meeting, May, 2001.
8. Mihara K, Dome JS, Vanin E, Campana D. Development of continuously growing human bone marrow stromal cell lines with enhanced supporting capacity by enforced expression of telomerase reverse transcriptase. Proceedings ASH, 2001.
9. Dome JS, Bockhold C, Wu J, and Drissi R. Telomere integrity as a determinant of radiation sensitivity in human cells. Molecular Genetics of Aging, Cold Spring Harbor Meeting, October, 2002.
10. Dome JS, Bockhold C, Wu J, Daw NC, and Drissi R. Alternative Lengthening of Telomeres (ALT) is the Predominant Mechanism for Telomere Maintenance in Human Osteosarcoma, AACR Conference on the Role of Telomeres and Telomerase in Human Cancer, San Francisco, December, 2002.
11. Bakkenist CJ, Drissi R, Wu J, Kastan MB, and Dome JS. ATM activation by telomere dysfunction during cellular aging but not in senescence. Proceedings AACR, 45: 2405, 2004.
12. Dome JS, Bockhold CA, Li SM, Green DM, Baker S, Perlman EJ, Hill DA, Breslow NE. Telomerase RNA expression as a prognostic marker in patients with favorable histology Wilms tumor. Proceedings ASCO, 22: 803S, 2004.
13. Sanders RP, Drissi R, Billups CA, Daw NC, Gayed P, Valentine MB, and Dome JS. Telomere Maintenance Mechanism Predicts Clinical Behavior in Human Osteosarcoma,

AACR Conference on the Role of Telomeres and Telomerase in Human Cancer, San Francisco, November, 2004.

14. Dome JS, Green DM, Cotton C, Breslow NE, Perlman E, Miser J, Ritchey ML, Shamberger RC, Thomas PRM, Grundy P, and the National Wilms Tumor Study Group. Treatment of Anaplastic Wilms Tumor: A Report from the National Wilms Tumor Study Group. *Proceedings ASCO*, 23: 802S, 2005.
15. Dome JS, Neale G, Hill DA, Perlman EJ, Pei D, Cheng C, and Houghton PJ. Antitumor activity of topotecan against Wilms tumor: Translation of a xenograft model to a phase II study, *Pediatr Blood Cancer*, 45: 432, 2005.
16. Kalapurakal J, Anderson J, Peterson S, Shamberger R, Ritchey M, Haase G, Thomas P, Dome J, Green D, D'Angio G, and Grundy P. Treatment outcomes in children with favorable histology Wilms tumor and peritoneal implants-a report from the National Wilms Tumor Study -4 and -5. *Pediatr Blood Cancer*, 45: 389, 2005.
17. Perotti D, De Vcchi G, Sardella M, Grundy PE, Dome J, Bassi C Fossati-Bellani F, and Radice P. Germline POU6F2 Mutations in Wilms Tumor Patients. *Pediatr Blood Cancer*, 45: 423, 2005.
18. Dome J, Freeman B, Billups C, Hoffer F, Wu J, Coppes M, Grant R, Chintagumpala M, Mullen E, Alvarado C, Daw N, Stewart C, and Metzger M. Anti-tumor activity of topotecan against Wilms tumor: Results of a multi-institutional phase II study. *Pediatr Blood Cancer*, 47: 453, 2006.
19. Kalapurakal J, Dome J, Perlman E, Seibel N, Haase G, Ritchey M, Thomas P, D'Angio G, and Grundy P. Optimal therapy for stage I clear cell sarcoma of the kidney-A report from the National Wilms Tumor Study. *Pediatr Blood Cancer*, 47: 383, 2006.
20. Williams RD, Natrajan R, Al-Saadi R, Little S, Hing S, Mackay A, Fenwick K, Ashworth A, Grundy P, Dome JS, Pritchard-Jones K, Jones C. Array comparative genomic hybridization and expression profiling of Wilms tumor identify molecular correlates of histology and relapse, *Proc AACR*, 2007.
21. Aldred MA, Ruteshouser EC, Natrajan R, Grundy PE, Dome JS, Huff V, Jones C. Loss of heterozygosity analysis of sporadic Wilms tumor defines at least one novel tumor suppressor locus at chromosome 2q37, *Proc AACR*, 2007.
22. Kalapurakal JA, Gopalakrishnan M, Shore R, Zhang Y, Fernandez C, Tochner Z, Paulino A, Dome J, V. Sathiaselan¹, A. Kepka. Feasibility And Potential Utility Of Cardiac-sparing Lung Imrt In Children With Wilms Tumor: A dosimetry study, *Proc ASTRO*, 2009.

23. Hu, Y and Dome JS. The effect of protracted telomerase inhibition with GRN163L on pediatric cancer cell lines. Proc of the 7th International Conference on the Biology of Pediatric Renal Tumors, Banff, Canada, 2010.
24. Mullen EA, Anderson JR, Steacy KJ, Geller JI, Green DM, Norkool P, Fernandez CV, Khanna G, Malogolowkin MH, and Dome JS. The impact of surveillance imaging on overall survival in patients with recurrent Wilms Tumor: A Report from the Children's Oncology Group, Proc ASCO, 2011
25. Malogolowkin M, Spreafico F, Dome J, Breslow N, van Tinteren H, Pritchard-Jones K, van den Heuvel M, Bergeron C, De Kraker J, Graf N. Incidence and outcomes of patients with late recurrence of Wilms tumor (WT): The international experience, Proc ASCO, 2011
26. Ehrlich P, Ou S, Ritchey M, Hamilton T, Green D, Dome J, Grundy P, Perlman E, Kalapurakal J, Breslow N, Shamberger R. Clinico-pathologic findings predictive of relapse in children with stage III favorable histology Wilms tumor: the importance of lymph nodes. Proc, Amer Surg Assoc, 2011
27. Ragg S, Key M, McMahon A, Bhattacharjee M, Gulati K, Joshi A, Lee ND, Schadow G, Gorlick R, Dome JS, and Grundy PE. Protein signatures in the serum of patients with osteosarcoma and Wilms tumor. *Pediatr Blood Cancer*, 59 (6): 1009, 2012.
28. Mullen EA, Gooskens SLM, Hamilton TE, van den Heuvel-Eibrink MM, Green DM, Grundy PE, Daw NC, Dome JS, Fernandez CV. Sinusoidal obstruction syndrome during treatment for renal tumors in NWTs 3, 4, and 5: Incidence, severity and effect on planned treatment and outcome. *Pediatr Blood Cancer*, 59 (6): 1010, 2012.
29. Mullen EA, Geller JI, Gratias EJ, Perlman EJ, Ehrlich PF, Khanna G, Naranjo A, He Y, Hamilton T, Ferrer FA, Glick RD, Gow KW, Barnhart D, Kandel J, Dasgupta R, Hoffer FA, Servaes S, Fernandez CV, Grundy PE, Dome JS. Real-time central review: A report of the first 3,000 patients enrolled on the Children's Oncology Group Renal Tumor Biology and Risk Stratification protocol AREN03B2. *J Clin Oncol*, 32: 5s, abstr 10000, 2014.
30. Daw NC, Anderson JR, Hoffer FA, James I. Geller, Kalapurakal JA, Perlman EJ, Ehrlich PF, Mullen EA, Gratias E, Grundy PE, Dome JS. A Phase 2 Study of Vincristine and Irinotecan in Metastatic Diffuse Anaplastic Wilms Tumor: Results from the Children's Oncology Group AREN0321 Study, *J Clin Oncol* 32:5s, abstr 10032, 2014.
31. Dix D, Gratias E, Seibel N, Anderson J, Mullen E, Geller J, Khanna G, Kalapurakal J, Perlman E, Ehrlich P, Malogolowkin M, Grundy P, Dome JS. Treatment of Stage IV Favorable Histology Wilms tumor with Incomplete Lung Metastasis Response after Chemotherapy: A report from Children's Oncology Group Study AREN0533, *J Clin Oncol*, 32: 5s, abstr 10001, 2014.

49. P. Ehrlich, E.M. Mullen, J. Geller, A. Naranjo, E. Gratias, D. Barnhart, R. Dasgupta, F. Ferrar, K. Gow, R. Glick, T. Hamilton, J. Kandel, H.E. Ying, E. Pearlman, J. Kalapurakal, J. Dome. Unilateral Wilms Tumor Treated By Partial Nephrectomy Enrolled On The Children's Oncology Group (Cog) Renal tumor Biology And Classification Study AREN03B2. *Pediatr Blood Cancer* DOI 10.1002/pbc, 2014.
50. N. Daw, J. Anderson, J. Kalapurakal, F. Hoffer, J. Geller, E. Perlman, P. Ehrlich, E. Mullen, A. Warwick, P. Grundy, J. Dome. Treatment Of Stage II-IV Diffuse Anaplastic Wilms Tumor: Results From the Children's Oncology Group Aren0321 Study. *Pediatr Blood Cancer* DOI 10.1002/pbc, 2014
51. Mullen EA, Geller JI, Gratias E, Perlman EJ, Ehrlich PF, Khanna G, Naranjo A, Fernandez CV, Gow K, Ferrer F, Hamilton T, Glick J, Kandel J, Barnhart D, He Y, Dasgupta R, Hoffer F, Servaes S, Gastier-Foster J, Hill DA, Huff V, Grundy PE, and Dome JS. Comprehensive Update of Pediatric Renal tumor Epidemiology: Analysis of The First 4000 Patients on Children's Oncology Group (Cog) Renal Tumor Classification and Biology Protocol Aren03b2. *Pediatr Blood Cancer* DOI 10.1002/pbc, 2014.
52. Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry-Auvil J, Dome JS, van den Heuvel-Eibrink MM, de Krijger RR, and Perlman EJ Are There Anaplastic Wilms Tumors That Retain An Intact P53 Pathway? *Pediatr Blood Cancer* DOI 10.1002/pbc, 2014.
53. Dix DB, Fernandez CV, Chi Y-Y, Anderson J, Mullen E, Geller J, Gratias E, Khanna G, Kalapurakal J, Perlman EJ, Seibel N, Ehrlich P, Malogolowkin M, Gow K, Hamilton T, Grundy P, Dome JS. Augmentation of therapy for favorable histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children's Oncology Group studies AREN0532 and AREN0533, *J Clin Oncol* 33: suppl abstr 10009, 2015.
54. Fernandez CV, Mullen EA, Ehrlich PF, Kalapurakal J, Khanna G, Chi Y, Perlman E, Paulino A, Hamilton TE, Gow KW, Ferrer FA, Tochner Z, An Q, Hoffer F, Withycombe J, Shamberger R, Geller JI, Anderson JR, Grundy PE, and Dome JS. Outcome and prognostic factors in Children's Oncology Group (COG)-defined stage III Favorable Histology Wilms Tumor (FHWT). A report from COG study AREN0532, *J Clin Oncol* 33: suppl abstr 10010, 2015.
55. Dix DB, Gratias E, Seibel N, Anderson J, Mullen E, Geller J, Khanna G, Kalapurakal J, Perlman EJ, Ehrlich P, Malogolowkin M, Grundy P, Dome JS. Omission of Lung Radiation in Patients with Stage IV Favorable Histology Wilms tumor (FHWT) Showing Complete Lung Nodule Response after Chemotherapy: A Report from Children's Oncology Group Study AREN0533, *J Clin Oncol* 33: suppl abstr 10011, 2015.

56. Fernandez CV, Perlman EMullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer F, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Qi A, Geller JI, Grundy PE, Anderson JR, Dome JS and Shamberger RC. Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Children's Oncology Group AREN0532. J Clin Oncol 33: suppl abstr 10023, 2015.
57. Ooms AHAG, Gadd S, Gerhard DA, Smith M, Guidry JM, Auvin D, . Meerzaman D, Ma Y, Marra MA, Huff V, Dome JS, Chi YY, Geller JI, Mullighan CG, Wheeler DA, Hampton OA, Van den Heuvel-Eibrink MM, DeKrijger RR, Ross N, Gastier-Foster JM, and Perlman EJ. Prognostic Impact of TP53 Mutation Status in Wilms Tumors with Diffuse Anaplasia. Pediatr Blood Cancer 2016; 63: S5–S
58. Daw NC, Chi YY, Mullen EA, J.A. Kalapurakal, J. Tian, G. Khanna, J.I. Geller, E.J. Perlman, P.F. Ehrlich, A.B. Warwick, C.V. Fernandez, P.E. Grundy, J.S. Dome. Treatment of Stage I Focal or Diffuse Anaplastic Wilms Tumour: A report from the Children's Oncology Group. Pediatr Blood Cancer 2016; 63: S5–S
59. P. Ehrlich, E. Smith, G. Khanna, K. Gow, T. Hamilton, S. Servaes, D. Barnhardt, R.Glick, R. Dasgupta, F. Ferrar, E. Mullen, J. Geller, C. Fernandez, J. Kalapurakal, E. Gratias, J. Dome, D. Dix. Feasibility of Complete Resection of Residual Lung Nodules after Chemotherapy in Patients with Stage IV Favorable Histology Wilms Tumour. Pediatr Blood Cancer 2016; 63: S5–S
60. R. Venkatramani, Y.Y. Chi, M. Coppes, M. Malogolowkin, J. Kalapurakal, J. Tian, J, and Dome JS. Outcomes of Patients with Wilms Tumour and Brain Metastases Enrolled on National Wilms Tumour Studies 1-5: A Report from the Children's Oncology Group Pediatr Blood Cancer 2016; 63: S5–S
61. D.B. Dix, E. Gratias, N.L. Seibel, Y.Y. Chi, J. Tian, E. Mullen, J. Geller, G. Khanna, J. Kalapurakal, E.J. Perlman, P. Ehrlich, M. Malogolowkin, P. Grundy, J.S. Dome Treatment of Stage IV Favorable Histology Wilms Tumour with Extra-Pulmonary Metastases: A Report from Children's Oncology Group Study AREN0533. Pediatr Blood Cancer 2016; 63: S5–S
62. M. Nelson, Y. Liu, C. Bailey, Y. Liu, J. Dome, Y. Wang. Highly-Accumulated HIF-1A is a Potential Therapeutic Target in the Treatment of Wilms Tumor. Pediatr Blood Cancer 2017, DOI: 10.1002/pbc.26772
63. E. Mullen, E. Perlman, Y.Y. Chi, D. Dix, G. Eric, J.Gastier-Foster, G. Khanna, P. Ehrlich, J. Geller, J. Kalapurakal, C. Fernandez, J. Dome. Impact OF 1Q Status on Outcomes of Stage IV Favorable Histology Wilms Tumor (FHWt) Patients Treated on the Children's Oncology Group (COG) Study AREN0533. Pediatr Blood Cancer 2017, DOI: 10.1002/pbc.26772

64. N. Daw, Y.Y. Chi, Y. Kim, J.A. Kalapurakal, F. Hoffer, J. Geller, E. Perlman, P. Ehrlich, K. Gow, E. Mullen, A. Warwick, P. Grundy, E.J. Gratias, D. Ward, J.R. Anderson, A.D.C. Paulino, Z. Tochner, R. Venkatramani, C. Fernandez, J. Dome. Effect of Chemotherapy Dosage on Outcome of Patients with Stage II-IV Diffuse Anaplastic Wilms Tumor: Results from the Children's Oncology Group AREN0321 Study
Pediatr Blood Cancer 2017, DOI: 10.1002/pbc.26772
65. P. Ehrlich, E. Smith, G. Khanna, K. Gow, T. Hamilton, S.E.N.Servaes, D. Barnhart, R. Glick, R. Dasgupta, E. Mullen, J. Geller, C. Fernandez, J. Kalapurakal, E. Gratias, J. Dome, D. Dix. Feasibility of Complete Resection of Residual Lung Nodules After Chemotherapy in Patients with Stage IV Favorable Histology Wilms Tumor
Pediatr Blood Cancer 2017, DOI: 10.1002/pbc.26772
66. J. Geller, Y.Y. Chi, J. Kalapurakal, N. Daw, F. Hoffer, E. Perlman, P. Ehrlich, E. Mullen, A. Warwick, A. Paulino, Z. Tochner, K. Gow, P. Grundy, E. Gratias, D. Ward, J. Anderson, C. Fernandez, J. Dome. Treatment of Extra-Cranial Malignant Rhabdoid Tumor: Results from the Children's Oncology Group AREN0321 Study.
Pediatr Blood Cancer 2017, DOI: 10.1002/pbc.26772
67. Geller JI, Cost NG, Chi YY, Perlman EJ, Kim Y, Cajaiba M, Mullen EA, Glick RD, Khanna G, Daw NC, Ehrlich PF, Fernandez CV, and Dome J. A prospective study of pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN0321. J Clin Oncol 36, 2018 (suppl; abstr 10516)

Videos

1. Sanger JM, Dome JS, Mittal B, Somlyo AV and Sanger JW: Dynamics of the endoplasmic reticulum in living cells. Cell Motil.Cytoskel. Video Suppl. 3, Chapter 7,1992.
2. Sanger JM, Mittal B, Dome JS and Sanger JW: Analysis of cell division using fluorescently labeled actin and myosin in living cells.Cell Motil. Cytoskel. Video Suppl.#4, Chapter 3, 1994.
3. Sanger JM, Dome JS, Hock R, Mittal B and Sanger JW: Occurrence of fibers and their association with talin in the cleavage furrow of PtK2 cells. Cell Motil. Cytoskel. Video Suppl.#5, Chapter 3, 1998.

PRESENTATIONS

Regional

Johns Hopkins University School of Medicine, Baltimore, MD, Urology Grand Rounds, "Wilms Tumor." October, 1997.

St. Jude Children's Research Hospital, "Management of Wilms tumor with CT-only lung nodules", April, 1999

St. Jude Children's Research Hospital, "Clinical Significance of Nephrogenic Rests in Wilms tumor," June, 2000.

St. Jude Children's Research Hospital, "Rhabdomyomatous Wilms tumor," March, 2001

St. Jude Children's Research Hospital, "Malignant Rhabdoid Tumor," April, 2001

St. Jude Children's Research Hospital, "Recurrent Wilms Tumor," November, 2001

St. Jude Children's Research Hospital, "Telomeres, Telomerase, and DNA Repair," May, 2002

St. Jude Children's Research Hospital, "Significance of Nuclear Unrest in Wilms Tumor," January, 2003

St. Jude Children's Research Hospital, "All's Well that Ends Well: Consequences of Telomere Dysfunction," August, 2003.

St. Jude Children's Research Hospital, "Management of Bilateral Wilms Tumor," December, 2003

St. Jude Children's Research Hospital, "Chemotherapy Dosing in Infants," February, 2004

St. Jude Children's Research Hospital, "Telomere Biology: Translation of Basic Science Observations to the Clinic," September, 2004.

St. Jude Children's Research Hospital, "End of Life Considerations in Children with Refractory Cancer," January, 2005.

St. Jude Children's Research Hospital, "Wilms Tumor and the Pulmonary Nodule Question," October, 2005.

St. Jude Children's Research Hospital, "Genetic Mysteries of Familial Wilms Tumor," March, 2006.

University of Tennessee Health Sciences Center, "Wilms Tumor," October, 2006.

Inova Fairfax Hospital, Pediatric Grand Rounds, "Pediatric Oncology: Lessons Learned from Wilms Tumor," September, 2007.

Children's National Medical Center, Pediatric Grand Rounds, "Advances in Pediatric Oncology: Lessons Learned from Wilms Tumor," September, 2008.

Children's National Medical Center, Pediatric Grand Rounds, McKnew Professorship Lecture, "All's Well that End's Well: The Telomere Biology of Pediatric Cancer," May 2011.

National

St. Jude Children's Research Hospital, "Telomerase as a Predictor of Relapse in Wilms Tumor." June, 1997.

Pediatric Oncology Group, Education Session, Chicago, IL, "Telomerase in the Prognosis and Therapy of Cancer: Hope or Hype?" October, 1998.

Children's Oncology Group, Education Session, Tampa, FL, "Telomerase as a Prognostic Indicator and Therapeutic Target for Pediatric Cancer," April, 2000.

National Institutes of Health Osteosarcoma Biology Workshop, Bethesda, MD, "Telomeres and Telomerase in Osteosarcoma," November, 2001.

NIH Special Conference on Osteosarcoma Biology, Chicago, IL, "Telomere Maintenance Mechanisms in Osteosarcoma," February, 2004.

Yale University School of Medicine, New Haven, CT, "Telomere Maintenance and Signaling in Human Cells," April, 2004.

Children's Memorial Hospital, Chicago, IL, "Targeting Chromosome Ends: Applying Telomere Biology to Treat Pediatric Cancer," February, 2005.

Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, Visiting Professor, "Wilms Tumor Biology: Current Status and Future Challenges." March, 2007.

Uniformed Services University of Health Sciences, Bethesda, MD, "Wilms tumor 2007: A progress report," June, 2007.

National Institutes of Health, Pediatric Oncology Branch, "All's Well that Ends Well: Telomere Biology of Pediatric Cancer," June, 2007.

American Society of Pediatric Hematology/Oncology, Invited Speaker, "Where There's a Wilms, There are Many Ways," Cincinnati, Ohio, May, 2008.

University of Texas Southwestern Hematology/Oncology Grand Rounds, "What's New with Wilms Tumor?" Dallas, TX, February, 2009.

CureSearch Conference on High-Risk Pediatric Kidney Tumors, Meeting Organizer, Bethesda, MD, February, 2009.

American Society of Clinical Oncology Annual Meeting, Invited Discussant for Pediatric Oncology Session, Orlando, FL, June, 2009.

American Society of Clinical Oncology Annual Meeting, Symposium Chair and speaker, “Wilms tumor: Unsettled questions and controversies” Chicago, IL, June 2010.

Young Investigator Symposium, Children’s Oncology Group, Keynote Speaker, “Pearls for Young Investigators: How to Navigate COG and Build a Successful Research Career,” Dallas, TX, September 2010

Pablove Foundation Symposium, “Wilms Tumor Biology: What are the Remaining Pieces of the Puzzle?” Los Angeles, CA, November 2010.

American Urological Association, “The Collateral Damage of Curing Pediatric Genitourinary Cancers,” Washington DC, May 2011.

Caroline Symmes Foundation Lectureship, “Wilms Tumor: Finding the Recipe for Success,” Riley Children’s Hospital, Indianapolis, IN, June, 2013.

Chard Lecture, Pediatrics Grand Rounds, “Wilms Tumor: Finding the Best Recipe for Successful Treatment,” Children’s Hospital Seattle, Seattle Washington, November, 2013.

Pediatric Grand Rounds, “Wilms Tumor: Finding the Recipe for Successful Treatment,” Miami Children’s Hospital, February, 2014

Grand Rounds, “What’s New with Wilms Tumor,” Memorial Sloan Kettering Cancer Center, New York, May 2014

American Society of Clinical Oncology Annual Meeting, “Beyond Stage and Histology: New Approaches to Risk Stratification in Wilms Tumor, Chicago, IL, June 2014.

Grand Rounds, “Wilms Tumor: Finding the best recipe for successful treatment,” Montefiore Hospital, Bronx, NY, March 2015.

Grand Rounds, “Wilms Tumor: Finding the best recipe for successful treatment,” Westchester Medical Center, Valhalla, NY, March 2015.

Grand Rounds, “Wilms Tumor:” Columbia New York Presbyterian Hospital, New York, NY, December 2015

International

AHOPCA (Central American Society for Pediatric Hematology/Oncology) Annual Meeting, Roatan, Honduras, “What’s New in the Treatment of Wilms Tumor?,” February, 2001.

UKCCSG Biology of Childhood Cancer Meeting, London, UK, meeting moderator, Workshop on High-Risk Renal Tumours, December, 2002.

SIOP Renal Tumor Biology Meeting, Paris, France, “Telomerase Expression as a Prognostic Indicator for Wilms Tumor,” November, 2004.

5th International Conference of Childhood Renal Tumors, Vancouver, Canada, “Clinical and Biologic Advances in Anaplastic Wilms Tumor: A Progress Report,” September, 2005.

SIOP Meet the Expert Session, Geneva, Switzerland, “Malignant Rhabdoid Tumor,” September, 2006.

SIOP Meet the Expert Session, Geneva Switzerland, “Bilateral Wilms Tumor,” September, 2006.

SIOP Symposium Invited Speaker, Mumbai, India, “Wilms tumor Risk Stratification,” November, 2007.

Brazilian National Cancer Institute Meeting on Embryonal Tumors, Invited Speaker, “The Evolving Story of Wilms Tumor Biology,” Rio de Janeiro, Brazil, March, 2008.

6th International Conference on Pediatric Renal Tumor Biology, Meeting Organizer, Chamonix, France, March, 2008.

British Institute of Radiology, “Radiation Therapy for Wilms Tumor,” London, England, September, 2008.

Israeli Society of Pediatric Oncology, Invited Guest Speaker, “Advances in Wilms Tumor Therapy: The COG Approach,” Ramot, Israel, April, 2009.

“Early Detection of Recurrent Wilms Tumor: Does it Matter,” Amsterdam, The Netherlands, September, 2009

Sophia Children’s Hospital, Erasmus University, Pediatric Grand Rounds, “Advances in Pediatric Oncology: Lessons Learned from Wilms Tumor,” Rotterdam, The Netherlands, September, 2009

7th International Conference on Pediatric Renal Tumor Biology, Meeting Organizer and speaker, “The effect of protracted telomerase inhibition with GRN163L on pediatric cancer cell lines,” Banff, Canada, March 2010.

Japanese Society of Pediatric Oncology Presidential Symposium, “Current Therapy for Pediatric Kidney Tumors- The COG Approach,” Osaka, Japan, December 2010

Kyoto Prefectural University Grand Rounds, “Progress and Challenges in Pediatric Cancer Research in the United States,” Kyoto, Japan, December 2010.

1st International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma, Meeting organizer/host, Alexandria, VA, May 2011.

International Society of Pediatric Oncology Renal Tumor Study Group Annual Meeting, “Children’s Oncology Group Renal Tumor Trials,” Lyon, France, June 2011.

International Society of Pediatric Oncology Annual Meeting, Renal Tumor Symposium, Session Moderator, Auckland, New Zealand, October, 2011.

6th Annual International Pediatric Conference, United Arab Emirates, “Progress and Challenges in Pediatric Cancer Research,” Al Ain, Abu Dhabi, March, 2012.

European Network of Excellence for Cancer Research in Children and Adolescents (ENCCA), “Clinical and Biological Prognostic Factors for Pediatric Renal Tumors,” Rome, Italy, June 2012.

International Society of Pediatric Oncology Annual Meeting, Renal Tumor Symposium, Symposium Chair/Organizer, London England, October, 2012.

Southern Medical University, Nanfang Hospital, Visiting Professor, “Pediatric Cancer Research in the United States,” Guangzhou, China, December, 2012.

St. Jude-Viva Forum, “Treatment of Wilms Tumor: 2013,” Singapore, March, 2013.

8th International Conference on Pediatric Renal Tumor Biology, Conference Chair, Bethesda, MD, May, 2013.

International Society of Pediatric Oncology, “Effect of Telomerase Inhibition in Pre-Clinical Models of Rhabdoid Tumor,” Paris, France, December, 2013.

Shanghai Children’s Medical Center, Shanghai, China, “Progress and Challenges in Pediatric Cancer Research,” October, 2014.

National Center for Childhood Health and Development, Tokyo, Japan, “Progress and Challenges in Pediatric Cancer Research in the United States,” October, 2014.

Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada, “Renal Tumors in Adolescents and Young Adults: An Evolving Story,” November, 2014.

International Society of Pediatric Oncology, “Chemotherapy for Wilms tumor: Past, Present and Future,” Stockholm, Sweden, June 2015.

Emirates Oncology Conference, “Therapy for Wilms Tumor: the COG Perspective,” Abu Dhabi, UAE, November 2015.

Sino-US-Japan Translational Medicine Conference, “Precision Therapy for Wilms Tumor,” Shanghai, China, November 2015.

9th International Conference on Pediatric Renal Tumor Biology, Conference Organizer and Speaker, Toronto, Canada, April, 2016.

World Federation of Associations of Pediatric Surgeons’ Congress, “New Developments in the Treatment and Biology of Wilms Tumor,” Washington, DC, October, 2016.

20 Annual Conference of the Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics (PHOCON), “New Developments in Risk Stratification for Wilms tumor,” Mumbai, India, November, 2016.

International WAGR Syndrome Symposium, “WAGR Syndrome: Imaging Considerations,” Ann Arbor, MI, May, 2017.

International Society of Pediatric Oncology, Meeting Chair, Washington, DC, October, 2017.

Holistic View to the Future IV Pediatrics Conference, “Hot New Developments in Pediatric Oncology,” Kuwait, January, 2018.

St. Jude-VIVA Oncology Conference, “Wilms Tumor: New Insights from Recent COG Trials,” Singapore, March, 2018.

SIOP Renal Tumour Study Group Annual Meeting, “Update on COG Renal Tumor Trials,” Copenhagen, June, 2018.

XI Peruvian Society of Medical Oncology, “Wilms Tumor: Lessons Learned from Recent COG Trials,” Lima, Peru, October, 2018.

St. Jude-VIVA Oncology Conference, “Recent Advances in Wilms and Non-Wilms Pediatric Renal Tumors,” Shanghai, October, 2018